alexsl
ImmunityBio (NASDAQ:IBRX) has been upgraded to Overweight from Neutral at Piper Sandler due to strong commercial momentum for its lead candidate Anktiva.
The company’s successful launch of Anktiva in BCG-unresponsive carcinoma in situ non-muscle invasive bladder cancer has exceeded expectations, with